Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

d of 2008. The increase for the first quarter of 2009 was primarily due to increased employee expenses and increased costs associated with operating as a public company. The first quarter of 2008 also included $0.8 million in preferred share accretion, a non-cash item, which did not recur in the first quarter of 2009, as subsequent to the reverse takeover there are no longer any preferred shares outstanding.

The Company had $9.4 million in cash and cash equivalents as of March 31, 2009, compared to $12.4 million in cash, cash equivalents and short-term investments as of December 31, 2008. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations through February 2010. The Company had 5,549,905 shares outstanding as at May 3, 2009.

"This is an exciting time for OncoGenex as we continue to progress on our clinical, regulatory and commercial objectives for 2009," said Scott Cormack, President and Chief Executive Officer of OncoGenex. "The final comprehensive survival analysis from the randomized Phase 2 clinical trial which compared OGX-011 in combination with docetaxel and prednisone to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer will be featured during an oral presentation at the American Society of Oncology 2009 Annual Meeting. The oral presentation will update the preliminary survival data that was released in December 2008 that indicated that patients in the OGX-011 treatment group had a rate of death approximately 40% lower than patients receiving chemotherapy without OGX-011. A second oral presentation at the ASCO 2009 Annual Meeting will feature preliminary data from our ongoing Phase 1 clinical trial evaluating OGX-427 in patients with solid tumors."

Cormack added, "In relation to our Phase 3 regulatory strategy, we have now received confirmations on two separate Phase 3 trial designs from the FD
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Follow ... represents one of the fastest growing technologies in the ... in subcellular visualization is driving growth in nucleic acid ... deeper understanding of gene expressions will continue to benefit ... applications in fields ranging from pharma, biotech, food & ...
(Date:3/4/2015)... , March 4, 2015 ... Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen ... Royal Philips (NYSE: PHG, AEX: ... Röntgenkongress 2015 (ECR) bekannt, der vom 4. bis ... An den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... Present Company Overview-, PRINCETON, N.J. and SAN ... focused on the development of medicines with,novel mechanisms ... present a corporate overview at the 2008 BIO ... will summarize the,current status of the company including ...
... FREMONT, Calif., Oct. 23 WaferGen Biosystems,Inc. (OTC ... expression, genotyping, cell biology and stem cell research ... chief,executive officer, will deliver a corporate presentation at ... be held October 28-31, 2008,at the Palace Hotel ...
... Conference Call to be Held on November 13, 2008 ... / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ), a leading pharmaceutical, biotechnology ... and the,United States, today announced that it will release ...
Cached Biology Technology:Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum 2WaferGen to Present at the Seventh Annual BIO Investor Forum 2WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008 2
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Dec. 18, 2013 Tissue engineering is a ... or reparative medicine with potential to circumvent organ ... involve leveraging technologies from biomaterials, molecular medicine, biochemistry, ... and/or repair of human organs through regeneration and ...
... RICHLAND, Wash. Engineers have created a continuous chemical process ... harvested algae a verdant green paste with the ... the Department of Energy,s Pacific Northwest National Laboratory was reported ... company, Utah-based Genifuel Corp., has licensed the technology and is ...
... or Moderate Resolution Imaging Spectroradiometer instrument that flies aboard ... detected the heat from the Pfeiffer Fire near Big ... EST. The red outlined area represents the heat from ... has destroyed at least 15 homes and caused many ...
Cached Biology News:State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4Algae to crude oil: Million-year natural process takes minutes in the lab 2Algae to crude oil: Million-year natural process takes minutes in the lab 3
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... 10X concentrated solutions. REact Buffer SetConsists of one ... buffers and one 250 microl vial of 10 ... vials of REact 1 Buffer four 1 ml ... vials of REact 3 Buffer and four 1 ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
Biology Products: